Genetic variability in inflammation pathways and prostate cancer risk

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 3, 2007, Pages 250-259

  Sun, Jielin ^a   Turner, Aubrey ^a   Xu, Jianfeng ^a   Grönberg, Henrik ^b   Isaacs, William ^c  

^a WAKE FOREST UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic variability; Inflammation; MSR1; Mutation; Prostate cancer; RNASEL; SNP; TLR

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 8; PROTEIN MSR1; RIBONUCLEASE L; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER RISK; GENE CLUSTER; GENE IDENTIFICATION; GENE NUMBER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROSTATITIS; VARIATION (GENETICS);

EID: 34247646625     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.10.001     Document Type: Review

References (96)

1. Isaacs W.B., Xu J., and Walsh P.C. Hereditary prostate cancer. In: Chung L.W.K., Isaacs W.B., and Simons J.W. (Eds). Prostate cancer, biology, genetics, and the new therapeutics (2001), Humana Press, Totowa (NJ) 13-28
2. Gronberg H., Damber L., and Damber J.E. Studies of genetic factors in prostate cancer in a twin population. J Urol 152 (1994) 1484-1487
3. Page W.F., Braun M.M., Partin A.W., et al. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 33 (1997) 240-245
4. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000) 78-85
5. Carter B.S., Beaty T.H., Steinberg G.D., et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89 (1992) 3367-3371
6. Gronberg H., Damber L., Damber J.E., et al. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am J Epidemiol 146 (1997) 552-557
7. Schaid D.J., McDonnell S.K., Blute M.L., et al. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62 (1998) 1425-1438
8. Cui J., Staples M.P., Hopper J.L., et al. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 68 (2001) 1207-1218
9. Schaid D. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13 (2004) R103-R121
10. Balkwill F., and Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 357 (2001) 539-545
11. Nelson W.G., DeWeese T.L., and DeMarzo A.M. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21 (2002) 3-16
12. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
13. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
14. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274 (1996) 1371-1374
15. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30 (2002) 181-184
16. Silverman R.H. Implications for RNase L in prostate cancer biology. Biochemistry 42 (2003) 1805-1812
17. Hassel B.A., Zhou A., Sotomayor C., et al. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12 (1993) 3297-3304
18. Rokman A., Ikonen T., Seppala E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70 (2002) 1299-1304
19. Wang L., McDonnell S.K., Elkins D.A., et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 71 (2002) 116-123
20. Nakazato H., Suzuki K., Matsui H., et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 89 (2003) 691-696
21. Casey G., Neville P.J., Plummer S.J., et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32 (2002) 581-583
22. Xiang Y., Wang Z., Murakami J., et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res 63 (2003) 6795-6801
23. Wiklund F., Jonsson B.A., Brookes A.J., et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 10 (2004) 7150-7156
24. Maier C., Haeusler J., Herkommer K., et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 92 (2005) 1159-1164
25. Rennert H., Zeigler-Johnson C.M., Addya K., et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 14 (2005) 949-957
26. Rennert H., Bercovich D., Hubert A., et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 71 (2002) 981-984
27. Kotar K., Hamel N., Thiffault I., et al. The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 40 (2003) e22
28. Xu J., Zheng S.L., Komiya A., et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32 (2002) 321-325
29. Platt N., and Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? -The mouse's tale. J Clin Invest 1085 (2001) 649-654
30. Xu J., Zheng S.L., Komiya A., et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet 721 (2003) 208-212
31. Miller D.C., Zheng S.L., Dunn R.L., et al. Germ-line mutations of the macrophage scavenger receptor 1 gene: Association with prostate cancer risk in African-American men. Cancer Res 63 (2003) 3486-3489
32. Wang L., McDonnell S.K., Cunningham J.M., et al. No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet 35 (2003) 128-129
33. Seppala E.H., Ikonen T., Autio V., et al. Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 9 (2003) 5252-5256
34. Hope Q., Bullock S., Evans C., et al. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 142 (2005) 397-402
35. Lindmark F., Jonsson B.A., Bergh A., et al. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate 59 (2004) 132-140
36. Sun J., Hsu F.C., Turner A.R., et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 66 (2006) 728-737
37. Singh B.P., Chauhan R.S., and Singhal L.K. Toll-like receptors and their role in innate immunity. Curr Sci 85 (2003) 1156-1164
38. Barton G.M., and Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270 (2002) 81-92
39. Werling D., and Jungi T.W. TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 91 (2003) 1-12
40. Hirschfeld M., Weis J.J., Toshchakov V., et al. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 69 (2001) 1477-1482
41. Birchler T., Seibl R., Buchner K., et al. Human toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 31 (2001) 3131-3137
42. Rescigno M., Granucci F., and Ricciardi-Castagnoli P. Molecular events of bacterial-induced maturation of dendritic cells. J Clin Immunol 20 (2000) 161-166
43. Bosisio D., Polentarutti N., Sironi M., et al. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: A molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 99 (2002) 3427-3431
44. Akira S. Toll-like receptor signaling. J Biol Chem 278 (2003) 38105-38108
45. Lakhani S.A., and Bogue C.W. Toll-like receptor signaling in sepsis. Curr Opin Pediatr 15 (2003) 278-282
46. Weighardt H., Kaiser-Moore S., Vabulas R.M., et al. Cutting edge: Myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 169 (2002) 2823-2827
47. Suzuki N., Suzuki S., Duncan G.S., et al. Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 416 (2002) 750-756
48. Schimke J., Mathison J., Morgiewicz J., et al. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci U S A 95 (1998) 13875-13880
49. Eisenbarth S.C., Piggott D.A., Huleatt J.W., et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 196 (2002) 1645-1651
50. de Kleijn D., and Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 60 (2003) 58-67
51. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 (2002) 185-192
52. Pirie F.J., Pegoraro R., Motala A.A., et al. Toll-like receptor 3 gene polymorphisms in South African Blacks with type 1 diabetes. Tissue Antigens 66 (2005) 125-130
53. Tsuji S., Matsumoto M., Takeuchi O., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68 (2000) 6883-6890
54. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
55. Zheng S.L., Augustsson-Balter K., Chang B., et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study. Cancer Res 64 (2004) 2918-2922
56. Sun J., Wiklund F., Zheng S.L., et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 977 (2005) 525-532
57. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 2825396 (1998) 2085-2088
58. Vogel S.N., Perera P.Y., Detore G.R., et al. CD14 dependent and independent signaling pathways in murine macrophages from normal and CD14 "knockout" (CD14KO) mice stimulated with LPS or taxol. Prog Clin Biol Res 397 (1998) 137-146
59. Ohashi K., Burkart V., Flohe S., et al. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164 (2000) 558-561
60. Chuang T., and Ulevitch R.J. Identification of hTLR10: A novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518 (2001) 157-161
61. Takeuchi O., Sato S., Horiuchi T., et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169 (2002) 10-14
62. Yamamoto M., Takeda K., and Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 40 (2004) 861-868
63. Takeuchi O., Kawai T., Muhlradt P.F., et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13 (2001) 933-940
64. Ozinsky A., Underhill D.M., Fontenot J.D., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 97 (2000) 13766-13771
65. Hajjar A.M., O'Mahony D.S., Ozinsky A., et al. Cutting edge: Functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 1661 (2001) 15-19
66. Janssens S., and Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 16 (2003) 637-646
67. Spitzer J.H., Visintin A., Mazzoni A., et al. Toll-like receptor 1 inhibits Toll-like receptor 4 signaling in endothelial cells. Eur J Immunol 32 (2002) 1182-1187
68. Bottner M., Suter-Crazzolara C., Schober A., et al. Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 2971 (1999) 103-110
69. Hromas R., Hufford M., Sutton J., et al. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354 (1997) 40-44
70. Thomas R., True L.D., Lange P.H., et al. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: Relation to tumor development and progression. Int J Cancer 931 (2001) 47-52
71. Nakamura T., Scorilas A., Stephan C., et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88 (2003) 1101-1104
72. Welsh J.B., Sapinoso L.M., Kern S.G., et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100 (2003) 3410-3415
73. Hsieh C.L., Oakley-Girvan I., Balise R.R., et al. A genome screen of families with multiple cases of prostate cancer: Evidence of genetic heterogeneity. Am J Hum Genet 69 (2001) 148-158
74. Wiklund F., Gillanders E.M., Albertus J.A., et al. Genome-wide scan of Swedish families with hereditary prostate cancer: Suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 57 (2003) 290-297
75. Lindmark F., Zheng S.L., Wiklund F., et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96 (2004) 1248-1254
76. Clay F.E., Cork M.J., Tarlow J.K., et al. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet 94 (1994) 407-410
77. Blakemore A.I., Cox A., Gonzalez A.M., et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 97 (1996) 369-374
78. El Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
79. Machado J.C., Pharoah P., Sousa S., et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121 (2001) 823-829
80. Lindmark F., Zheng S.L., Wiklund F., et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93 (2005) 493-497
81. Hochreiter W.W., Nadler R.B., Koch A.E., et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 56 (2000) 1025-1029
82. Alexander R.B., Ponniah S., Hasday J., et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 52 (1998) 744-749
83. Nadler R.B., Koch A.E., Calhoun E.A., et al. IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol 164 (2000) 214-218
84. Kim S.J., Uehara H., Karashima T., et al. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3 (2001) 33-42
85. McCarron S.L., Edwards S., Evans P.R., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62 (2002) 3369-3372
86. Bidwell J., Keen L., Gallagher G., et al. Cytokine gene polymorphism in human disease: On-line databases, supplement 1. Genes Immun 2 (2001) 61-70
87. Hull J., Thomson A., and Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55 (2000) 1023-1027
88. Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 (2002) 260-264
89. Ferrer F.A., Miller L.J., Andrawis R.I., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157 (1997) 2329-2333
90. Kammerer S., Roth R.B., Reneland R., et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 64 (2004) 8906-8910
91. Kretowski A., Wawrusiewicz N., Mironczuk K., et al. Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. J Clin Endocrinol Metab 88 (2003) 4945-4949
92. Matsuzawa J., Sugimura K., Matsuda Y., et al. Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut 52 (2003) 75-78
93. Nejentsev S., Laaksonen M., Tienari P.J., et al. Intercellular adhesion molecule-1 K469E polymorphism: Study of association with multiple sclerosis. Hum Immunol 64 (2003) 345-349
94. Ogawa Y., Hirakawa K., Nakata B., et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 4 (1998) 31-36
95. Yasuda M., Tanaka Y., Tamura M., et al. Stimulation of beta1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase. Cancer Res 61 (2001) 2022-2030
96. Maruo Y., Gochi A., Kaihara A., et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer 100 (2002) 486-490